Enoxaparin-induced hepatotoxicity: an under-recognised complication of enoxaparin therapy.
Low-molecular-weight heparins including enoxaparin are commonly used for anticoagulation as prophylaxis and treatment for deep vein thrombosis (DVT). Prescribers of enoxaparin monitor for common side effects, such as bleeding and thrombocytopenia, but hepatotoxicity, a less common and under-reported adverse effect, may be overlooked. This report describes a case of enoxaparin-induced hepatotoxicity in a 57-year-old man who was started on the drug for a DVT. Within 3 days of taking enoxaparin, elevated transaminases were noted, and the drug was discontinued after 6 days. Similar to other published reports, the patient's transaminases peaked 1 day after discontinuation of the drug and then trended down to normal over 32 days.
Alpert Medical School of Brown University, Providence, Rhode Island, USA.
Katie Ann
KA
Pivarnik
Brown Medical School/Rhode Island and Miriam Hospitals, Providence, Rhode Island, USA.
Fred
F
Schiffman
Department of Medicine, Warren Alpert School of Medicine, Brown University, The Miriam Hospital, Providence, Rhode Island, USA.
James
J
Sullivan
Department of Medicine, Warren Alpert School of Medicine, Brown University, The Miriam Hospital, Providence, Rhode Island, USA.
Arkadiy
A
Finn
Circulation. 2006 Apr 18;113(15):e698-702
16618822
Am Fam Physician. 2011 Nov 1;84(9):1003-8
22046940
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
7249508
Acta Med Scand. 1978;204(3):229-30
696422
Am J Health Syst Pharm. 2009 Apr 1;66(7):638-41
19299370
Pharmacotherapy. 2001 Jan;21(1):108-13
11191729
Clin Pharmacol Ther. 2012 Aug;92(2):214-20
22739141
Drug Saf Case Rep. 2015 Dec;2(1):17
27747729
Br Med J. 1975 Jul 12;3(5975):77
1139236
J Pain Palliat Care Pharmacother. 2008;22(1):45-46
28792816
J Clin Pharmacol. 2001 Jun;41(6):691-4
11402639